• Latest Posts

Manfred Horst on MSD, Biosimilars, KEYTRUDA and his Company’s rich history

What Happened this Week? Abbvie abandons Galapagos, CRISPR Patent war to end and AI to exploit UK’s 100k genomes

Merck relinquishes Rare Disease license to instead focus on Immuno-oncology

Asceneuron’s latest stab at the Alzheimer’s challenge with Sofinnova

Apitope relocates to Wales after €12M series B financing round

Could an Alpaca’s monoclonal antibodies be used to treat an ultra-rare blood disease?

ADVERTISEMENT

Crowdsourcing for Innovation: BioMed X has just the right Recipe

Startups receive €25K investment as part of Merck’s brand new Accelerator Program

Allergan Continues its Serial Acquisitions to be a Giant Drugmaker

Ablynx and MSD upgrade their €1.7Bn deal to gigantic €5.7Bn

Newron’s ressurection story continues with a FDA Orphan Drug designation

ADVERTISEMENT